1. Home
  2. LEGN vs CORT Comparison

LEGN vs CORT Comparison

Compare LEGN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

N/A

Current Price

$19.85

Market Cap

5.9B

Sector

Health Care

ML Signal

N/A

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

SELL

Current Price

$113.68

Market Cap

9.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LEGN
CORT
Founded
2014
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
9.7B
IPO Year
2020
2001

Fundamental Metrics

Financial Performance
Metric
LEGN
CORT
Price
$19.85
$113.68
Analyst Decision
Strong Buy
Buy
Analyst Count
12
5
Target Price
$61.33
$96.50
AVG Volume (30 Days)
2.0M
1.0M
Earning Date
05-12-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.09
Revenue
N/A
$761,407,000.00
Revenue This Year
$42.68
$26.08
Revenue Next Year
$30.52
$26.98
P/E Ratio
N/A
$1,299.22
Revenue Growth
N/A
12.79
52 Week Low
$16.24
$28.66
52 Week High
$37.50
$126.38

Technical Indicators

Market Signals
Indicator
LEGN
CORT
Relative Strength Index (RSI) 41.55 55.51
Support Level $17.01 $76.41
Resistance Level $23.66 $122.21
Average True Range (ATR) 1.02 3.86
MACD 0.18 -1.00
Stochastic Oscillator 7.41 29.60

Price Performance

Historical Comparison
LEGN
CORT

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: